Clinicopathologic profiling and oncologic outcomes of secretory carcinoma of the breast

Sci Rep. 2021 Jul 19;11(1):14738. doi: 10.1038/s41598-021-94351-w.

Abstract

Secretory carcinoma of the breast (SCB) is a rather rare entity of invasive breast cancer, the clinicopathologic characteristics and survival outcomes remain to be elaborated. A retrospective review was conducted in SEER database. A total of 190 SCB patients identified in SEER were eligible for inclusion in the analysis. Median age at diagnosis was 56 years (range 2-96 years). Both sexes and bilateral breast could be affected. Intriguingly, the incidence of SCB tended towards to decreasing in recent decades. Small tumor burden was observed with a mean tumor size of 2.13 cm. In a subgroup with sufficient details, positive staining of estrogen receptor (ER) and progesterone receptor (PR) was 58% and 40%, respectively. The vast majority of patients were of well to moderate differentiation (86.86%) and negative regional lymph nodes involvement (70.71%). Nearly half of the patients took radiotherapy and chemotherapy. Seniors were inclined to have an inferior breast cancer specific survival (BCSS) than their younger counterparts (P = 0.018). Patients underwent breast conserving surgery (BCS) and radiotherapy had much better BCSS than its mastectomy counterparts (P = 0.014). Collectively, SCB is a clinical indolent invasive breast cancer with excellent prognosis. BCS in conjunction with radiotherapy would be a rational alternative for this distinct entity.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Breast Neoplasms / diagnosis*
  • Breast Neoplasms / epidemiology*
  • Breast Neoplasms / pathology
  • Carcinoma / diagnosis*
  • Carcinoma / epidemiology*
  • Carcinoma / pathology
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Middle Aged
  • Prognosis
  • Retrospective Studies
  • Risk Factors
  • SEER Program
  • Socioeconomic Factors
  • United States / epidemiology
  • Young Adult

Supplementary concepts

  • Secretory breast carcinoma